We would love to hear your thoughts about our site and services, please take our survey here.
Major Shareholders:
NPIF YHTV Equity LP 27,041,240 19.6%
Octopus Investments 25,250,000 18.3%
Providence Holdings Limited1 15,402,830 11.2%
Sam ****erill2 14,245,000 10.3%
Janus Henderson 10,000,000 7.2%
Reyker Nominees Limited 6,141,660 4.4%
Lady Patricia Saxby & Sir Robin Saxby3 4,871,350 3.5%
Edward Haynes & Sarah Haynes4 4,460,770 3.2%
Total number of shares in issue: 138,089,010
The total number of shares in Ordinary Issue upon Admission is 138,089,010.
The percentage of shares not in the public hands is 61.8%.
1 Sam ****erill is also a director of Providence Holdings Limited.
2 The holdings of Samuel Edward ****erill are split between his personal holding (9.0%) and his investment vehicle, Sam ****erill Limited (1.3%)
3 The holdings of Lady Patricia & Sir Robin Saxby are split between Lady Patricia Saxby’s holding (2.2%) and Sir Robin Saxby’s holding (1.3%)
4 The holding of Edward Haynes & Sarah Hayes are split between Edward Watson Haynes holding (0.2%), Sarah Jayne Haynes holding (1.7%) and Edward Haynes investment vehicle’s holding, Watson Haynes Limited holding (1.4%)
After the recent placing and the subsequent SP adjustment I've now started topping up again (at 26.44p - which is being shown as a sell by LSE but then most of my BIRD buys show as sells - a largely irrelevant metric I know)
Looking forward to a, hopefully, happy new year as a BIRD investor. Merry xmas and GLA
I'm looking at getting back in tomorrow myself after previously holding then cashing out when the SP started to slide.
Results of the Clarava and Tuteva validation trials are due to be complete by the end of 2021 I believe. I wonder if this has anything to do with Harwood upping their holding.
I've answered my own question. This, of course, is just what was issued in the RNS yesterday
Reporting this morning that YGEN wins second Covid-19 surge testing contract. Is this new?
"Manchester biotech company Yourgene has been awarded a contract with the UK Health Security Agency to provide lab capacity to the NHS Test and Trace Programme for COVID-19 testing.
It is the second contract to be awarded to the group this year under the Public Health England National Microbiology Framework Agreement and will use Yourgene’s facilities in Citylabs 1.0, Manchester.
CEO Lyn Rees said: “We are thrilled to be supporting the Government’s COVID-19 testing programme, following on from the successful NHS Test and Trace Programme for COVID-19 testing contract we secured in August this year.
“The repeat business demonstrates the quality of services and testing facilities we offer at our laboratory in Manchester. Actual value for this contract will depend on the services purchased, with no committed spend at this moment in time, but we look forward to updating shareholders on the progress over time.”
From October but interesting interview with US investor Randy Baron
https://www.youtube.com/watch?v=MfRToHti858
Good to see the positive comments re: Pete. I worked for TW before for 40y before retiring and feel Pete did a tremendous job especially when TW were on the brink. All the best to him in his future life beyond TW.
Shame us lowly PI's were not included but I am, otherwise, seeing it as a very positive move and it's good to see they are doing a presentation on Investor Meets tomorrow to explain it all a bit more. I will be tuning in.